| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 03/27/1997 | CA2232301A1 Pskh-1 ribozymes and uses in disease treatment |
| 03/27/1997 | CA2231806A1 Dna construct comprising a muscle specific regulatory element for immunization or gene therapy |
| 03/27/1997 | CA2231172A1 Nucleic acid delivery vehicle |
| 03/27/1997 | CA2230138A1 Cyclin/cdk proteins, and uses related thereto |
| 03/27/1997 | CA2230127A1 Neutralizing monoclonal antibodies to respiratory syncytial virus |
| 03/27/1997 | CA2230116A1 Neutralizing monoclonal antibodies to respiratory syncytial virus |
| 03/27/1997 | CA2227306A1 Manipulation and detection of protein phosphatase 2c - pp2c.alpha. - expression in tumor cells for cancer therapy, prevention and detection |
| 03/26/1997 | EP0764213A1 Recombinant aav genome encoding immunodeficiency virus protein |
| 03/26/1997 | EP0764204A1 HUMAN OXALYL-CoA DECARBOXYLASE |
| 03/26/1997 | EP0764203A1 Methods for selectively stimulating proliferation of t cells |
| 03/26/1997 | CN1146155A Method for implanting encapsulated cells in a host |
| 03/26/1997 | CN1146136A Targeted cytolysis of HIV-infected cells by Chimeric CD4 receptor bearing cells |
| 03/25/1997 | US5614618 Origin of replication complex genes |
| 03/25/1997 | US5614617 Nuclease resistant, pyrimidine modified oligonucleotides that detect and modulate gene expression |
| 03/25/1997 | US5614609 Serine threonine kinase receptor |
| 03/25/1997 | US5614503 Spermine or spermidine linked to cholesterol, drug delivery |
| 03/25/1997 | US5614397 Method and compositions for modulating lifespan of hematolymphoid cells |
| 03/25/1997 | US5614187 Conferring tolerance to foreign tissue in recipient mammal |
| 03/20/1997 | WO1997010349A1 Materials and methods for treating neurodegenerative diseases and for screening for candidate apoptosis inhibitors and inducers |
| 03/20/1997 | WO1997010343A1 Circular dna molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
| 03/20/1997 | WO1997010337A1 Steroid receptor coactivator compositions and methods of use |
| 03/20/1997 | WO1997010335A1 Recombinant polypeptide based on the primary sequence of the invariant chain with at least one primary sequence of a specific t-cell epitope or a protein derivative and nucleic acids coding for this recombinant polypeptide |
| 03/20/1997 | WO1997010334A2 Ribozyme therapy for the treatment and/or prevention of restenosis |
| 03/20/1997 | WO1997010332A2 Chimaeric oligonucleotides and uses thereof in the identification of antisense binding sites |
| 03/20/1997 | WO1997010254A1 Oligomers which inhibit expression of collagen genes |
| 03/20/1997 | WO1997010249A1 Toxoplasma gondii glycoconjugates |
| 03/20/1997 | WO1997010007A1 Cancer treatment |
| 03/20/1997 | WO1997010006A1 Method for inhibiting cell-mediated killing of target cells |
| 03/20/1997 | WO1997010005A2 Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| 03/20/1997 | WO1997003187A3 Marek's disease virus genes and their use in vaccines for protection against marek's disease |
| 03/20/1997 | WO1997000952A3 A human edg-2 receptor homolog |
| 03/20/1997 | WO1996033271A3 Genetic markers for breast and ovarian cancer |
| 03/20/1997 | CA2232089A1 Oligomers which inhibit expression of collagen genes |
| 03/20/1997 | CA2232012A1 Toxoplasma gondii glycoconjugates |
| 03/20/1997 | CA2231850A1 Steroid receptor coactivator compositions and methods of use |
| 03/20/1997 | CA2231804A1 Method for inhibiting cell-mediated killing of target cells |
| 03/20/1997 | CA2231687A1 Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| 03/20/1997 | CA2231685A1 Ribozyme therapy for the treatment and/or prevention of restenosis |
| 03/20/1997 | CA2229307A1 Circular dna molecule with conditional origin of replication, method for preparing same and use thereof in gene therapy |
| 03/19/1997 | EP0763205A1 Nucleic acid sequences controlling lung cell-specific gene expression |
| 03/19/1997 | EP0763124A1 Method for introducing nucleic acid in higher eukaryotic cells |
| 03/19/1997 | EP0763123A1 Safe retroviral vectors, their production and use |
| 03/19/1997 | EP0763122A1 Retroviral gene therapy vectors and therapeutic methods based thereon |
| 03/19/1997 | EP0763121A1 Method of cancer treatment by p53 protein control |
| 03/19/1997 | EP0763120A1 Safe vectors for gene therapy |
| 03/19/1997 | EP0763116A1 Recombinant viruses, preparation and use thereof in gene therapy |
| 03/19/1997 | EP0763108A1 Dna sequences |
| 03/19/1997 | EP0763106A1 Methods and compositions for treatment of restenosis and cancer using ribozymes |
| 03/19/1997 | EP0763104A1 Human dna topoisomerase i-alpha |
| 03/19/1997 | EP0763052A1 ANTISENSE OLIGONUCLEOTIDE MODULATION OF raf GENE EXPRESSION |
| 03/19/1997 | EP0763051A1 3'-(4'-) nonradioactively tagged nucleosides and nucleotides with aminocarboxylic acid, peptide or carboxylic acid spacer |
| 03/19/1997 | EP0763050A1 Branched oligonucleotides as pathogen-inhibitory agents |
| 03/19/1997 | EP0763045A1 Haemopoietic maturation factor |
| 03/19/1997 | EP0762891A1 Immunogenic pharmaceuticals |
| 03/19/1997 | EP0762881A1 Method and reagents for the treatment of rheumatoid arthritis |
| 03/19/1997 | EP0762870A1 Virosome-mediated intracellular delivery of therapeutic agents |
| 03/19/1997 | EP0561965A4 Enhancement of musculature in animals |
| 03/19/1997 | CN1145638A Ribozymes targeting retroviral packaging sequence expression constructs and recombinant retroviruses containing such constructs |
| 03/19/1997 | CN1145636A Vascular endothelial growth factor 2 |
| 03/18/1997 | US5612318 Control of gene expression by ionizing radiation |
| 03/18/1997 | US5612206 Retrovirus infecting primate bone marrow cells and harvesting both non-adherent and adherent cells |
| 03/18/1997 | US5612179 Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| 03/18/1997 | US5612030 Anti-idiotype monoclonal antibody 1A7 and use for the treatment of melanoma and small cell carcinoma |
| 03/13/1997 | WO1997009442A1 Targeted nucleotide sequence delivery and integration system |
| 03/13/1997 | WO1997009441A2 Improved aav vectors for gene therapy |
| 03/13/1997 | WO1997009440A1 The use of the wap of mmtv regulatory sequences for targeted expression of linked heterologous genes in human mammary cells, including human mammary carcinoma cells |
| 03/13/1997 | WO1997009433A1 Cell-cycle checkpoint genes |
| 03/13/1997 | WO1997009428A2 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 03/13/1997 | WO1997009427A1 Vegf-related protein |
| 03/13/1997 | WO1997009425A1 Cerebellum-derived growth factors, and uses related thereto |
| 03/13/1997 | WO1997009070A1 Glucocorticoid enhancement of gene expression |
| 03/13/1997 | WO1997009069A1 Methods and compositions for nucleic acid targeting |
| 03/13/1997 | WO1997008955A1 Bacterial delivery system |
| 03/13/1997 | WO1997005256A3 Mammalian pro-hormone convertase |
| 03/13/1997 | WO1997005185A3 Multiblock biodegradable hydrogels for use as controlled release agents for drugs delivery and tissue treatment agents |
| 03/13/1997 | WO1997003345A3 Detection and quantification of human herpesvirus 7 by enzymic amplification dna virus dna |
| 03/13/1997 | CA2684425A1 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 03/13/1997 | CA2653566A1 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 03/13/1997 | CA2264835A1 Methods and compositions for nucleic acid targeting |
| 03/13/1997 | CA2231788A1 Targeted nucleotide sequence delivery and integration system |
| 03/13/1997 | CA2231400A1 Vegf-related protein |
| 03/13/1997 | CA2231190A1 Cell-cycle checkpoint genes |
| 03/13/1997 | CA2230758A1 Improved aav vectors for gene therapy |
| 03/13/1997 | CA2229345A1 Glucocorticoid enhancement of gene expression |
| 03/12/1997 | EP0761233A2 Transkaryotic implantation |
| 03/12/1997 | EP0760864A1 Dna encoding glutamate gated chloride channels |
| 03/12/1997 | EP0760860A1 Methods of in vivo gene delivery |
| 03/12/1997 | EP0760682A1 Gene transfer-mediated angiogenesis therapy |
| 03/12/1997 | EP0760675A1 Compositions comprising dna damaging agents and p53 |
| 03/12/1997 | EP0760602A1 Use of fas ligand to suppress lymphocyte-mediated immune responses |
| 03/12/1997 | EP0627001A4 Mammalian sos - a regulator/effector of tyrosine kinase signalling. |
| 03/11/1997 | US5610054 Enzymatic RNA molecule targeted against Hepatitis C virus |
| 03/11/1997 | US5610050 Methods of preventing viral replication |
| 03/11/1997 | US5610013 Method for diagnosing a disorder by determining expression of gage tumor rejection antigen precursors |
| 03/06/1997 | WO1997008331A1 Stimulation of homologous recombination in eukaryotic organisms or cells by recombination promoting enzymes |
| 03/06/1997 | WO1997008328A1 Selective elimination of t cells that recognize specific preselected targets |
| 03/06/1997 | WO1997008321A1 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 03/06/1997 | WO1997008319A1 Genetic alterations related to familial alzheimer's disease |
| 03/06/1997 | WO1997008310A1 Novel 3' terminal sequence of hepatitis c virus genome and diagnostic and therapeutic uses thereof |
| 03/06/1997 | WO1997008309A2 Ribozyme therapy for hepatitis b infections |